Fox Run Management’s Travere Therapeutics TVTX Stock Holding History

Fox Run Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$622K	Buy	+10,940	New	+$485K	0.1%	388
2025 Q4	–	Sell	-11,249	Closed	-$269K	–	1270
2025 Q3	$269K	Buy	+11,249	New	+$211K	0.04%	721
2025 Q2	–	Sell	-15,396	Closed	-$276K	–	1244
2025 Q1	$276K	Sell	15,396 -10,312	-40%	-$209K	0.04%	698
2024 Q4	$448K	Buy	+25,708	New	+$455K	0.08%	472
2024 Q3	–	Sell	-28,125	Closed	-$231K	–	1108
2024 Q2	$231K	Buy	+28,125	New	+$189K	0.04%	624
2024 Q1	–	Sell	-19,678	Closed	-$177K	–	1066
2023 Q4	$177K	Buy	+19,678	New	+$143K	0.05%	647
2023 Q3	–	Sell	-18,271	Closed	-$281K	–	1009
2023 Q2	$281K	Buy	+18,271	New	+$332K	0.08%	473
2018 Q1	–	Sell	-17,482	Closed	-$368K	–	929
2017 Q4	$368K	Buy	+17,482	New	+$400K	0.11%	390
2017 Q3	–	Sell	-12,700	Closed	-$246K	–	869
2017 Q2	$246K	Buy	+12,700	New	+$230K	0.09%	484
2016 Q1	–	Sell	-16,800	Closed	-$324K	–	560
2015 Q4	$324K	Buy	+16,800	New	+$336K	0.25%	139

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's TVTX Position: Q2 2026 in Review

Fox Run Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 10,940 shares worth $622K. The stake represents 0.1% of the portfolio and ranks #388 among its holdings. This is a return to the name: Fox Run Management previously reported a position in TVTX as recently as Q3 2025.

Fox Run Management first reported a position in TVTX in Q4 2015 and has held it in 10 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Fox Run Management held 10,940 shares of Travere Therapeutics worth $622K as of Q2 2026.
Travere Therapeutics was a new Fox Run Management position in Q2 2026.
Travere Therapeutics made up 0.1% of Fox Run Management's portfolio in Q2 2026, its #388 holding.
Fox Run Management first reported a position in Travere Therapeutics in Q4 2015 and has held it in 10 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.